CorMedix to Showcase Innovations at Investor Conferences
CorMedix Inc. (Nasdaq: CRMD), a notable biopharmaceutical firm dedicated to advancing treatments for critical conditions, is set to engage investors through a series of discussions and presentations at key industry conferences this September. This initiative underscores the company’s commitment to communicating its strategic vision and innovative product pipeline to the investment community.
Cantor Global Healthcare Conference Details
The first major event is the Cantor Global Healthcare Conference, which takes place on September 5, 2025. At this conference, CorMedix will host a fireside chat scheduled for 8:35 AM Eastern Time. This format allows for an intimate setting where insights about the company's direction can be shared, fostering a deeper understanding of their innovations and market strategies. Investors and attendees interested in the details can participate via the webcast.
Participation in the Morgan Stanley Annual Global Healthcare Conference
Following the Cantor conference, CorMedix will also participate in the esteemed Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, with a fireside chat set for 10:45 AM Eastern Time. This event is another platform for CorMedix to connect with investors and present updates on their therapeutic products and market insights.
About CorMedix and Their Leading Product
CorMedix specializes in developing and commercializing therapeutic products aimed at combating life-threatening diseases. Their flagship product, DefenCath (combining taurolidine and heparin), was granted FDA approval in November 2023. The company successfully launched DefenCath in inpatient facilities in April 2024, followed by an outpatient rollout in July 2024. Moving forward, CorMedix has initiated clinical studies targeting Total Parenteral Nutrition and pediatric patient populations in 2025, expanding its utility to various patient demographics. Moreover, they plan to develop DefenCath as a catheter lock solution for other populations, emphasizing their innovative approach to treatment.
Engagement with Investors
Investors keen on learning more can expect comprehensive insights during these conferences, as senior management will be addressing both the potential of DefenCath and the company’s broader strategic vision. The team at CorMedix believes that these interactions are vital for gaining investor confidence and showcasing the company’s advancements in therapeutic solutions.
Contact Information
For those interested in more personalized discussions, the investor relations contact is Dan Ferry, Managing Director at LifeSci Advisors. He is available at daniel@lifesciadvisors.com or by phone at (617) 430-7576.
Frequently Asked Questions
What is CorMedix Inc. focused on?
CorMedix Inc. is dedicated to developing and commercializing therapeutic products for life-threatening conditions.
When are the upcoming investor conferences for CorMedix?
CorMedix will participate in the Cantor Global Healthcare Conference on September 5, 2025, and the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025.
What is DefenCath?
DefenCath is CorMedix's leading product, combining taurolidine and heparin, approved by the FDA to prevent serious health complications.
How can investors connect with CorMedix?
Investors can connect through presentations at the conferences or contact the investor relations representative, Dan Ferry, via email or phone.
What are CorMedix's future plans with DefenCath?
CorMedix plans to expand the indications for DefenCath through clinical studies and intends to develop it as a catheter lock solution for additional patient populations.
